Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OSMITROL 10% IN WATER IN PLASTIC CONTAINER vs MANNITOL 15%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Increases plasma osmolality, drawing water from tissues into the bloodstream, thereby reducing intracranial pressure and cerebral edema.
Increases plasma osmolality, drawing water from intracellular and interstitial spaces into the vascular compartment, thereby reducing intracranial pressure and intraocular pressure. Acts as an osmotic diuretic in the kidneys, increasing urine flow by inhibiting water reabsorption in the proximal tubule and loop of Henle.
Reduction of intracranial pressure,Reduction of cerebral edema,Promotion of diuresis in oliguric phase of acute renal failure
Reduction of intracranial pressure (FDA-approved),Reduction of intraocular pressure (FDA-approved),Promotion of diuresis in oliguric phases of acute renal failure (off-label),Cerebral edema (off-label)
Initial: 0.25–1 g/kg (25–100 m L of 10% solution) IV over 30–60 minutes. May repeat every 6–12 hours if needed. Typical adult dose: 50–100 g IV. Maximum: 2 g/kg per dose.
1-2 g/kg as a 15% solution intravenously over 30-60 minutes. Typical adult dose: 100-200 g (667-1333 m L of 15% solution) administered as a single dose for reduction of intracranial pressure or promotion of diuresis.
Terminal half-life approximately 1.5 hours in normal renal function; prolonged in renal impairment (up to 36 hours in anuria).
Terminal elimination half-life approximately 0.25-1.5 hours in normal renal function; prolonged to 24-36 hours in renal impairment.
Primarily excreted unchanged by the kidneys; not metabolized.
Mannitol is not significantly metabolized; it is primarily excreted unchanged by the kidneys via glomerular filtration.
Primarily renal; >90% excreted unchanged in urine via glomerular filtration; <5% biliary/fecal.
Primarily renal (90-100% as unchanged drug); negligible biliary/fecal elimination.
Negligible (<10%); does not significantly bind to plasma proteins.
Approximately 0-10% bound to plasma proteins (negligible binding).
Vd ~0.5 L/kg; distributes primarily in extracellular fluid, excluding cells.
0.5-0.8 L/kg; primarily distributes in extracellular fluid (interstitial space).
Not applicable (administered intravenously only); bioavailability is 100% by IV route.
Intravenous: 100% (only route used therapeutically); not administered orally due to minimal absorption (oral bioavailability < 5%).
Contraindicated in anuria or severe renal impairment (GFR <10 m L/min). In patients with GFR 10–50 m L/min, reduce dose by 50% and monitor serum osmolarity and urine output. Do not use if oliguria persists after test dose (0.2 g/kg IV over 3–5 minutes).
Contraindicated in anuria due to severe renal disease. For GFR <50 m L/min, use with caution and monitor serum osmolarity and renal function. No specific dose reduction defined; consider alternative therapy if GFR <20 m L/min.
No specific Child-Pugh based adjustment. Use with caution in severe hepatic impairment due to potential for fluid overload and electrolyte disturbances. Monitor serum electrolytes and hepatic function.
No specific adjustment for Child-Pugh class. Use with caution in ascites or severe hepatic impairment due to risk of volume overload and electrolyte disturbances.
Oliguria: Test dose 0.2 g/kg (2 m L/kg of 10% solution) IV over 3–5 minutes. If urine output >40 m L/hr, maintenance dose: 0.25–1 g/kg (2.5–10 m L/kg) IV over 30–60 minutes every 6–12 hours. Maximum: 2 g/kg per dose. Reduce intracranial pressure: 0.25–1 g/kg IV over 30–60 minutes.
0.25-1 g/kg (1.67-6.67 m L/kg of 15% solution) intravenously over 30-60 minutes. Repeat doses as needed based on clinical response, up to 1-2 g/kg.
Start at lower end of dosing range (0.25 g/kg) due to age-related decline in renal function. Monitor renal function, serum osmolarity, electrolytes (especially sodium and potassium), and fluid balance closely. Avoid use if GFR <50 m L/min unless benefit outweighs risk.
Initiate with lower doses (e.g., 0.5 g/kg) and titrate carefully due to increased risk of volume overload, electrolyte imbalance, and renal impairment. Monitor renal function, serum osmolarity, and fluid status closely.
Not approved for use in patients with severe renal impairment, anuria, or intracranial hemorrhage with active bleeding.
None
Monitor renal function, fluid and electrolyte balance, and serum osmolality. Use caution in patients with cardiac or pulmonary congestion, and administer via a filter to prevent crystallization.
May cause volume expansion, pulmonary congestion, or heart failure in patients with cardiac dysfunction. Monitor serum electrolytes, osmolality, and renal function. Use with caution in patients with renal impairment, as accumulation can cause metabolic acidosis. Risk of osmotic nephrosis or acute kidney injury with high doses or prolonged use. May exacerbate intracranial hemorrhage due to increased cerebral blood volume.
Anuria, severe renal impairment, pulmonary congestion, active intracranial hemorrhage, severe dehydration, known hypersensitivity to mannitol.
Anuria due to severe renal disease, severe pulmonary congestion or edema, active intracranial bleeding (except during craniotomy), severe dehydration, and known hypersensitivity to mannitol.
No specific food interactions. Maintain adequate hydration as directed. Avoid excessive salt intake to minimize fluid retention.
No significant food interactions. Avoid excessive sodium intake to prevent fluid retention.
Osmitrol 10% (mannitol) is a hyperosmolar agent. There are no adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. In first trimester, use only if clearly needed. In second and third trimesters, mannitol can cross the placenta and may cause fetal dehydration, electrolyte disturbances, and osmotic shifts. Risk cannot be excluded.
Mannitol is a category C drug. First trimester: No well-controlled studies, but animal studies have not shown teratogenic effects; risk cannot be excluded. Second and third trimesters: Use only if clearly needed, as osmotic diuresis may cause fetal dehydration, electrolyte imbalances, or altered placental blood flow. There is no evidence of direct teratogenicity.
It is not known whether mannitol is excreted in human breast milk. No M/P ratio is available. Caution should be exercised when administered to a nursing woman. Consider the developmental and health benefits of breastfeeding alongside the mother's clinical need for the drug.
Mannitol is not known to be excreted into human milk. M/P ratio is not established due to lack of data. Due to its high molecular weight and poor oral bioavailability, infant exposure via breastfeeding is likely negligible. Use with caution in lactating women only if clearly needed.
Pregnancy increases glomerular filtration rate, which may enhance mannitol elimination, but dosage adjustments are not established. Maintain standard dosing (generally 50-200 g over 24 hours). Monitor clinical response and urine output. No routine pharmacokinetic-based dose adjustment recommended.
No specific dose adjustments are recommended for pregnancy; however, pharmacokinetic changes in pregnancy (increased plasma volume and renal clearance) may require higher doses to achieve desired effect. Monitor clinical response and adjust dosing based on urine output and serum osmolality.
Osmítrol 10% is a hyperosmotic agent used to reduce intracranial pressure and cerebral edema. Administer via IV infusion using an in-line filter to prevent particulate embolism. Monitor serum osmolarity and sodium levels; discontinue if osmolarity exceeds 320 m Osm/L. Ensure adequate hydration to avoid hypovolemia. Use with caution in patients with renal impairment, congestive heart failure, or pulmonary congestion. Crystallization may occur at low temperatures; warm to redissolve crystals before use.
Monitor serum osmolality and electrolyte levels closely during therapy; use in cerebral edema requires maintaining serum osmolality 310-320 m Osm/L. Administer via in-line filter (0.22 micron) to prevent crystal emboli. Rapid infusion may cause transient hypervolemia; caution in heart failure or renal impairment. Onset of diuresis is 1-3 hours after IV administration.
This medication is given intravenously to reduce swelling in the brain.,You may experience a headache, nausea, or increased thirst during infusion.,Report any signs of allergic reaction (rash, itching, difficulty breathing) immediately.,You will be monitored with blood tests to check kidney function and electrolyte levels.,Avoid rapid position changes to prevent dizziness due to fluid shifts.,Do not stop this medication abruptly; follow your healthcare provider's instructions.
This medication increases urine output to reduce fluid buildup.,Report any chest pain, difficulty breathing, or swelling in ankles/feet.,You may experience headache, nausea, or dry mouth.,Avoid excessive salt intake to prevent fluid retention.,Notify your doctor if you have kidney disease or heart conditions.
No interactions on record
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OSMITROL 10% IN WATER IN PLASTIC CONTAINER vs MANNITOL 15%, answered by our medical review team.
OSMITROL 10% IN WATER IN PLASTIC CONTAINER is a Osmotic Diuretic that works by Increases plasma osmolality, drawing water from tissues into the bloodstream, thereby reducing intracranial pressure and cerebral edema.. MANNITOL 15% is a Osmotic Diuretic that works by Increases plasma osmolality, drawing water from intracellular and interstitial spaces into the vascular compartment, thereby reducing intracranial pressure and intraocular pressure. Acts as an osmotic diuretic in the kidneys, increasing urine flow by inhibiting water reabsorption in the proximal tubule and loop of Henle.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OSMITROL 10% IN WATER IN PLASTIC CONTAINER and MANNITOL 15% depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OSMITROL 10% IN WATER IN PLASTIC CONTAINER is: Initial: 0.25–1 g/kg (25–100 m L of 10% solution) IV over 30–60 minutes. May repeat every 6–12 hours if needed. Typical adult dose: 50–100 g IV. Maximum: 2 g/kg per dose.. The standard adult dose of MANNITOL 15% is: 1-2 g/kg as a 15% solution intravenously over 30-60 minutes. Typical adult dose: 100-200 g (667-1333 m L of 15% solution) administered as a single dose for reduction of intracranial pressure or promotion of diuresis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OSMITROL 10% IN WATER IN PLASTIC CONTAINER and MANNITOL 15% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OSMITROL 10% IN WATER IN PLASTIC CONTAINER is classified as Category C. Osmitrol 10% (mannitol) is a hyperosmolar agent. There are no adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. In first trimester, us. MANNITOL 15% is classified as Category A/B. Mannitol is a category C drug. First trimester: No well-controlled studies, but animal studies have not shown teratogenic effects; risk cannot be excluded. Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.